Elial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase > 자유게시판

Elial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT11). Cancer Lett. 2002;179:165?3. 32. Fardell JE, Vardy J, Monds LA, Johnston IN. The longterm impact of oxali platin chemotherapy on rodent cognition and peripheral neuropathy. Behav Brain Res. 2015;291:80?. 33. Nukatsuka M, Nakagawa F, Takechi T. Efficacy of combination chemother apy using a novel oral chemotherapeutic agent, TAS102, with oxaliplatin on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35:4605?5. 34. Armstrong T, Packham G, Murphy LB, Staurosporine Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP. Type I collagen promotes the malig nant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:7427?7. 35. Drifka CR, Tod J, Loeffler AG, Liu Y, Thomas GJ, Eliceiri KW, Kao WJ. Periductal stromal collagen topology of pancreatic ductal adenocarci noma differs from that of normal and chronic pancreatitis. Mod Pathol. 2015;28:1470?0. 36. Ornitz DM, Hammer RE, Messing A, Palmiter RD, Brinster RL. Pancreatic neoplasia induced by SV40 Tantigen expression in acinar cells of trans genic mice. Science. 1987;238:188?3. 37. Ding L, Han L, Li Y, Zhao J, He P, Zhang W. Neurogenin 3directed cre deletion of Tsc1 gene causes PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25751659 pancreatic acinar carcinoma. Neoplasia. 2014;16:909?7. 38. Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol. 2013;3:296. 39. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247?0. 40. Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res. 2013;19:6716?9. 41. Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, GandourEdwards R, Cooke DT, Yoneda KY, et al. Bridging tumor genom ics to patient outcomes through an integrated patientderived xenograft platform. Clin Lung Cancer. 2015;16:165?2. 42. Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, Eugster E, Scott SB, Beuschel NL, Davidson PJ, et al. Using a rhabdo myosarcoma patientderived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer. 2014;61:1570?. 43. Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT is an effective strategy for basallike breast cancer in patientderived xenograft models. Mol Cancer Ther. 2013;12:1665?5. 44. Scott C, Becker MA, Haluska P, Samimi G. Patientderived xenograft mod els to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013;3:295. 45. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, et al. Endocrinetherapyresistant ESR1 variants revealed by genomic characterization of breastcancerderived xenografts. Cell Reports. 2013;4:1116?0. 46. Kopetz S, Lemos R, Powis G. The promise of patientderived xenografts: the best laid plans of mice and men. Clin Cancer Res. 2012;18:5160?. 47. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Nicolanto nio F, Buscarino M. A molecularly annotated platform of patientderived xenografts ("Xenopatients") identifies HER2 as an effective therapeu tic target in cetuximabresistant colorectal cancer. Cancer Discov. 2011;1:508?3.48. T.